The Impact of Different rs3917538 Genotypes with the PON-1 Activity, Atherosclerosis Severity in Patients of Coronary Atherosclerosis
DOI:
https://doi.org/10.3889/oamjms.2022.8031Keywords:
Coronary atherosclerosis, PON-1 activity, rs3917538, Atherosclerosis severityAbstract
Background: Coronary atherosclerosis is one of the coronary artery diseases (CAD) responsible for a significant percentage of mortality and morbidity in Iraqi subjects. Atherosclerosis compresses about 17 million death cases; 45% are under the age of 70. The improvement in atherosclerosis disease management paly a critical role in preventing this disease; despite that, new risk factors have been studied, including genetic studies. Many polymorphisms have been associated with coronary atherosclerosis in different ethnic populations. Paraoxonase is an enzyme located on HDL in serum. PON acts as a protective factor or agent against oxidative modification of LDL, suggesting that it could play an essential and influential role in atherosclerotic processes prevention.
Objective: To evaluate the rs3917538 genotypes in the PON-1 gene associated with the coronary atherosclerosis risk and the effect of this single nucleotide polymorphism on the serum activity of PON-1 and the severity of coronary atherosclerosis.
Methods: A case-control study included sixty patients diagnosed with coronary atherosclerosis and sixty healthy volunteers diagnosed with angiography examination. The study was carried out during the period from February 2019 till June 2020. Serum PON-1 was measured by fluorometric technique, and the genetic assessment was by RT-PCR technique.
Results: The activity for PON-1 in patients was significantly lower than controls; the median activity of PON-1 in controls was 197.32 mU/ml, which was higher than that of patients (median =163.46 mU/ml). There was an impact of rs3917538 genotypes on the severity of the disease, P=0.041. The rs3917538 genotypes have no association with the risk of coronary atherosclerosis and the activity of PON-1.
Conclusion: The measurement of serum PON-1 activity may help in the diagnosis of coronary atherosclerosis patients. The rs3917538 genotypes in the PON-1 gene among the patient’s group impact the severity of coronary atherosclerosis.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Wang J, Wang LJ, Zhong Y, Gu P, Shao JQ, Jiang SS, Gong JB. CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population. Lipids Health Dis. 2013;12:176. https://doi.org/10.1186/1476-511X-12-176 PMid:24283500 DOI: https://doi.org/10.1186/1476-511X-12-176
Malin R, Järvinen O, Sisto T, Koivula T, Lehtimäki T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. Atherosclerosis. 2001;157(2):301-7. https://doi.org/10.1016/s0021-9150(00)00728-0 PMid:11472729 DOI: https://doi.org/10.1016/S0021-9150(00)00728-0
Ruiz J, Blanché H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in Type 2 diabetes. Lancet. 1995;346(8979):869-72. https://doi.org/10.1016/s0140-6736(95)92709-3 PMid:7564671 DOI: https://doi.org/10.1016/S0140-6736(95)92709-3
Bhaskar S, Ganesan M, Chandak GR, Mani R, Idris MM, Khaja N, et al. Association of PON1 and APOA5 gene polymorphisms in a cohort of Indian patients having coronary artery disease with and without Type 2 diabetes. Genet Test Mol Biomarkers. 2011;15(7-8):507-12. https://doi.org/10.1089/gtmb.2010.0207 PMid:21438666 DOI: https://doi.org/10.1089/gtmb.2010.0207
Fallah S, Seifi M, Ghasemi A, Firoozrai M, Samadikuchaksaraei A. Matrix metalloproteinase‐9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects. J Clin Lab Anal. 2010;24(5):305-10. https://doi.org/10.1002/jcla.20406 PMid:20872564 DOI: https://doi.org/10.1002/jcla.20406
Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol. 1997;17(11):2935-9. https://doi.org/10.1161/01.atv.17.11.2935 PMid:9409279 DOI: https://doi.org/10.1161/01.ATV.17.11.2935
Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998;139(2):341-9. https://doi.org/10.1016/s0021-9150(98)00095-1 PMid:9712341 DOI: https://doi.org/10.1016/S0021-9150(98)00095-1
Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors. 2009;35(1):98-104. https://doi.org/10.1002/biof.16 PMid:19319852 DOI: https://doi.org/10.1002/biof.16
Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioğlu E, Altintaş N, et al. The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol Dern Ars. 2009;37(7):473-8. PMid:20098041
Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: A brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018;14:137-43. https://doi.org/10.2147/VHRM.S165173 PMid:29950852 DOI: https://doi.org/10.2147/VHRM.S165173
Perła-Kaján J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino acids. 2012;43(4):1405-17. https://doi.org/10.1007/s00726-012-1321-z PMid:22643843 DOI: https://doi.org/10.1007/s00726-012-1321-z
Manly KF. Reliability of statistical associations between genes and diseases. Immunogenetics. 2005;57:549-58. https://doi.org/10.1007/s00251-005-0025-x PMid:16086172 DOI: https://doi.org/10.1007/s00251-005-0025-x
Arikan GD, Isbir S, Yilmaz SG, Isbir T. Characteristics of coronary artery disease patients who have a polymorphism in the cholesterol ester transfer protein (CETP) gene. In Vivo. 2019;33(3):787-792. https://doi.org/10.21873/invivo.11540 PMid:31028198 DOI: https://doi.org/10.21873/invivo.11540
Wysocka A, Cybulski M, P Wysokiński A, Berbeć H, Stążka J, Zapolski T. Paraoxonase 1 activity, polymorphism and atherosclerosis risk factors in patients undergoing coronary artery surgery. J Clin Med. 2019;8(4):441. https://doi.org/10.3390/jcm8040441 PMid:30935088 DOI: https://doi.org/10.3390/jcm8040441
Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69(4):541-50. https://doi.org/10.1016/j.bcp.2004.08.027 PMid:15670573 DOI: https://doi.org/10.1016/j.bcp.2004.08.027
Downloads
Published
How to Cite
License
Copyright (c) 2022 Noor K. Habash, Omar F. Abdul-Rasheed, Moayed B. Hamid (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0